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Tetsuyo Nishihara, Nao Suzuki*, Masahiro Yoneda and Takao HirofujiAbstract
Background: To evaluate the effects of the lactic acid bacterium Lactobacillus salivarius on caries risk factors.
Methods: The study was performed in 64 healthy volunteers to evaluate the effects of L. salivarius-containing
tablets on caries risk factors. The participants were divided randomly into four groups, and took tablets containing
L. salivarius WB21, L. salivarius TI 2711, Ovalgen® DC (antibody against glucosyltransferase from Streptococcus
mutans), or xylitol. Levels of mutans streptococci and lactobacilli, amount of salivary flow, salivary pH, and salivary
buffering capacity were assessed before and after taking the tablets. Subsequently, a short-term administration
trial using L. salivarius WB21-containing tablets was performed in eight healthy volunteers. The participants took
L. salivarius WB21-containing tablets (2.0 × 109 colony forming units/day) for 2 weeks, and the numbers of mutans
streptococci in saliva were counted.
Results: The levels of mutans streptococci seemed to decrease in the L. salivarius WB21, TI 2711, and Ovalgen®
DC groups compared to the xylitol group, with no significant differences between the groups. Lactobacilli levels
significantly increased in the L. salivarius WB21 and TI 2711 groups compared to the other groups. Concerning
salivary flow and salivary pH, no significant differences were observed between the groups. The salivary buffering
capacity significantly increased in the L. salivarius TI 2711 group (P = 0.003) and Ovalgen® DC group (P = 0.002)
compared to the xylitol group. The short-term administration trial showed that the L. salivarius WB21-containing
tablets significantly decreased the number of mutans streptococci (P = 0.039).
Conclusion: L. salivarius-containing tablets were suggested to increase resistance to caries risk factors.
Trial registration: UMIN000013160 (registration date: February 14, 2014).
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Beneficial microorganisms, or probiotics, have various
functions including antibacterial activities [1], modula-
tion of the host immune response [2], antiallergic effects
[3], and cancer prevention in the human intestine [4]. A
number of studies using lactic acid bacteria for the
prevention of oral diseases have been reported [5-10].
Probiotic bacteria in the human oral cavity include
Bifidobacterium species and Lactobacillus species [11].
Oral administration of Lactobacillus salivarius WB21-
containing tablets and oil reduced plaque accumulation,* Correspondence: naojsz@college.fdcnet.ac.jp
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unless otherwise stated.periodontal pocket depth, bleeding on probing, and oral
malodor [7-10]. L. salivarius TI 2711 showed antibacterial
activity against Porphyromonas gingivalis in mixed culture
experiments [12], and a clinical trial indicated that the
number of P. gingivalis in subgingival plaque was reduced
by oral administration of L. salivarius TI 2711-containing
tablets but recovered following cessation of tablet ad-
ministration [13]. However, there have been no reports
regarding caries prevention and control by L. salivarius.
Lactobacillus species are microbial markers of dental
caries risk [14]. Some species of lactobacilli have been
reported to occur in large numbers in both superficial
and deep caries [15,16]. However, several Lactobacillus
species have been isolated from healthy mouths [17,18].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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plaque would be considered a side effect of probiotic
lactobacilli. Most studies of caries prevention and con-
trol by lactic acid bacteria were performed over the last
few years. Lactobacillus species, including Lactobacillus
rhamnosus, Lactobacillus reuteri, and Lactobacillus para-
casei, that were investigated in previous clinical trials did
not alter or reduce mutans streptococci levels [19-21]. No
adverse effects or potential risks of these bacteria were
reported. In the present study, the potential effects of tab-
lets containing L. salivarius WB21 or TI 2711 on caries
risk factors were compared with tablets containing an
antibody against Streptococcus mutans and those contain-
ing only xylitol as controls. In addition, oral administra-
tion of L. salivarius WB21-containing tablets for 2 weeks




The tablets used in this study are listed in Table 1. The tab-
lets containing L. salivarius WB21 (Minna No Zendamakin
WB21 Tablet®; Wakamoto Pharmaceutical Co., Tokyo,
Japan) contained 6.7 × 108 colony-forming units (CFU)
of L. salivarius WB21 and 280 mg of xylitol per tablet.Table 1 Study population and products used in the study [n (
Group (n) L. salivarius WB21 L. sa
Item (n = 17) (n =
Age 24.0 (23.0 to 25.0) 24.0
Female (%) 9 (52.9) 6 (37
Mutans streptococci level (%)
Class 0 10 (58.8) 10 (6
Class 1 2 (11.8) 2 (12
Class 2 3 (17.6) 2 (12
Class 3 2 (11.8) 2 (12
Lactobacilli level (%)
Class 0 5 (62.5) 6 (75
Class 1 0 (0.0) 1 (12
Class 2 3 (37.5) 1 (12
Class 3 0 (0.0) 0 (0.
Salivary flow (mL per 3 min) 4.8 (3.3 to 5.8) 7.3 (
Salivary pH 7.7 (7.6 to 7.9) 7.9 (
Buffering capacity 5.7 (5.2 to 6.1) 6.1 (




Active ingredient (per tablet) L. salivarius WB21: 6.7 × 108 CFU L. sa
2.8 ×
Xylitol: 280 mg Xylit
Flavor Mint CleaThe tablets containing L. salivarius TI 2711 (Super Kurish;
Frente International Co., Tokyo, Japan) contained 2.8 ×
108 CFU of L. salivarius TI 2711 and 450 mg of xyli-
tol per tablet. The Ovalgen® DC-containing tablets (Hakira;
BeanStalk, Tokyo, Japan) contained egg yolk anti-
bodies against glucosyltransferase of S. mutans and
100 mg of xylitol per tablet. The xylitol-containing tab-
lets contained 280 mg of xylitol per tablet (Wakamoto
Pharmaceutical Co.).
Study population
Sixth-year dental students at Fukuoka Dental College
were recruited for an open-label comparative trial, and
64 volunteers (25 females and 39 males; mean age, 24.8 ±
2.3 years) were included in the study. Short-term ad-
ministration of L. salivarius WB21-containing tablets
was performed in eight healthy volunteers (four females
and four males, mean age, 30.0 ± 5.2 years), all of whom
were dentists working at Fukuoka Dental College Medical
and Dental Hospital, Fukuoka, Japan. The eligibility cri-
teria were as follows: not currently visiting a dentist for
treatment, no antibiotic use within 3 months, and no ad-
verse reactions to lactose or fermented milk products. All
subjects understood the nature of the research project and
provided written, informed consent prior to enrollment.%) or median (IQR)]
livarius TI 2711 Ovalgen® DC Xylitol
16) (n = 13) (n = 18)
(23.0 to 25.0) 24.0 (23.0 to 25.0) 24.5 (23.0 to 26.0)
.5) 4 (30.8) 6 (33.3)
2.5) 2 (15.4) 9 (50.0)
.5) 4 (30.8) 5 (27.8)
.5) 3 (23.1) 2 (11.1)
.5) 4 (30.8) 2 (11.1)
.0) 4 (57.1) 5 (71.4)
.5)) 1 (14.3) 2 (28.6)
.5) 2 (28.6) 0 (0.0)
0) 0 (0.0) 0 (0.0)
5.8 to 8.8) 6.5 (3.5 to 7.0) 5.5 (3.6 to 7.0)
7.7 to 7.9) 7.7 (7.5 to 7.9) 7.7 (7.6 to 8.0)
5.9 to 6.1) 5.9 (5.2 to 6.2) 5.9 (5.6 to 6.3)
r Kurish (Frente
national Co.)




Ovalgen® DC Xylitol: 280 mg
ol: 450 mg Xylitol: 100 mg
n mint Orange Mint
Nishihara et al. BMC Oral Health 2014, 14:110 Page 3 of 7
http://www.biomedcentral.com/1472-6831/14/110Permission for the study was obtained from the Ethics
Committee for Clinical Research of Fukuoka Dental




The trial was carried out from May to June in 2013 at
Fukuoka Dental College Medical and Dental Hospital,
Fukuoka, Japan. The participants were randomly divided
into four groups in a lottery, and took L. salivarius
WB21-containing tablets (n = 17), L. salivarius TI 2711-
containing tablets (n = 16), Ovalgen® DC-containing
tablets (n = 13), or xylitol-containing tablets (n = 18)
(Table 1). They were directed to place a tablet on the
tongue for a few minutes and allow it to dissolve.
Levels of mutans streptococci and lactobacilli, amount
of salivary flow, salivary pH, and salivary buffering
capacity were assessed before and after taking the
tablets.
The level of mutans streptococci was evaluated using
Dentocult® SM Strip mutans (Orion Diagnostica, Espoo,
Finland). First, the participants chewed paraffin gum for
3 min to stimulate the secretion of saliva and to transfer
mutans streptococci from tooth surfaces into the saliva.
Next, they pressed the test strip against the saliva on the
tongue. The test strip was attached to the cap in the
selective culture broth and the vial was recapped. After
incubation at 37°C for 48 h, the results were classified
into four classes (0–3) according to the model chart.
The colony counts of mutans streptococci were recorded
if possible. Table 2 shows the criteria used to evaluate
changes in mutans streptococci level before and after
taking the tablets.
The level of lactobacilli was evaluated using Dentocult®
LB (Orion Diagnostica) in half of the participants in
each group. One milliliter of saliva collected by the gum
test was applied to the culture medium and cultivated at
37°C for 96 h. Changes in lactobacillus level before andTable 2 Criteria for evaluating changes in levels of mutans
streptococci and lactobacilli
Score Criterion
−3 Going down more than two classes
−2 Going down a class
−1 Same class and decrease in colony numbers
0 No change
+1 Same class and increase in colony numbers
+2 Going up a class
+3 Going up more than two classes
Note: As an example, a score of “+2” indicates that the class of Dentocult® SM
increased one level after taking a tablet compared with the level before taking
a tablet.after taking the tablets were evaluated according to the
same criteria using Dentocult® SM (Table 2).
Salivary pH values both before and after addition of
acid (to assess salivary buffer capacity) were investigated
in the remaining saliva (CheckBuf test kit; Morita,
Osaka, Japan). The amount of salivary flow was assessed
by the gum test.
Short-term administration trial
The trial was carried out from February to March 2014.
The participants were asked to take L. salivarius WB21-
containing tablets for 2 weeks. The dose throughout the
test period was maintained at one tablet three times per
day, taken orally, after eating and mouth cleaning. Par-
ticipants were directed to place a tablet on the tongue
for a few minutes and allow it dissolve. They were also
instructed not to change their oral hygiene regimens and
not to take other probiotic products throughout the
study period. Neither professional prophylaxis nor tooth-
brushing instruction was performed before or during the
experimental period. Collecting saliva was performed at
least 4 h after eating lunch. The selective medium for
mutans streptococci was Mitis Salivarius Agar (Difco,
Tokyo, Japan) supplemented with 20% sucrose and baci-
tracin (0.2 units/mL) (Sigma, St. Louis, MO) [22]. Stimu-
lated saliva was collected by chewing gum for 3 min and
diluted, and the number of colonies was calculated after
anaerobic incubation at 37°C for 48 h.
Statistical analysis
The Kruskal-Wallis test was to test for differences
among the four groups in the open-label comparative
trial. The Wilcoxon rank-sum test was used to compare
pairs of groups in the open-label comparative trial. The
Wilcoxon signed-rank test was used to evaluate the
difference in mutans streptococci level between day 0
and day 14 in the short-term administration trial with
L. salivarius WB21-containing tablets. Statistical analyses
were conducted using the R software package, version




Baseline data for the study population are shown in
Table 1. Mutans streptococci were detected in 69% of
the study population (44/64) at baseline by Dentocult®
SM. Although the mutans streptococci level in the Oval-
gen® DC group seemed to be different from that in the
other groups, no statistically significant differences were
noted in mutans streptococci levels at baseline among
the groups.
Changes in the levels of mutans streptococci and lacto-
bacilli, salivary flow, salivary pH, and salivary buffering
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significant difference was detected between the changes in
mutans streptococci levels among the four groups. How-
ever, the levels of mutans streptococci seemed to decrease
in the L. salivarius WB21, TI 2711, and Ovalgen® DC
groups [median 0.0 (IQR −0.1 to 0.0), 0.0 (0.0 to 1.3), and
0.0 (−1.0 to 1.0), respectively] compared to the xylitol
group [0.0 (0.0 to 2.0)].
A significant difference was observed in the levels
of lactobacilli among the four groups (P < 0.001). The
levels of lactobacilli increased markedly in both the L.
salivarius WB21 and TI 2711 groups [median 3.0
(IQR 2.0 to 3.0) and 2.5 (2.0 to 3.0), respectively],
and were significantly higher than those in the other
two groups [0.0 (0.0 to 0.5) and 0.0 (−0.3 to 0.0), respect-
ively]. The presence of viable lactobacilli in these tablets
was confirmed.
No significant differences were observed in salivary
flow and salivary pH among the four groups. However,
salivary flow (mL per 3 min) tended to decrease in the
Ovalgen® DC and xylitol groups [median −0.5 (IQR −1.0
to 0.0) and −0.5 (−1.1 to 0.0), respectively], but not in
the L. salivarius WB21 and L. salivarius TI 2711 groups
[0.0 (−0.5 to 0.0) and 0.0 (−0.4 to 0.5), respectively]. Saliv-
ary pH tended to increase in the L. salivarius TI 2711 and
Ovalgen® DC groups [median 0.2 (IQR 0.0 to 0.3) and 0.1
(0.0 – 0.2), respectively].
Significant differences were detected in salivary buffer-
ing capacity among the four groups (P = 0.004). The sal-
ivary buffering capacity decreased in the xylitol group
[median −0.3 (IQR −0.6 to −0.1)], but increased in the
Ovalgen® DC group [0.2 (0.0 to 0.3)], while no changes
were observed in the salivary buffering capacity in the
L. salivarius WB21 and TI 2711 groups [median 0.0
(IQR −0.4 to 0.3) and 0.0 (−0.2 to 0.4), respectively].
Comparative analysis showed that there were significant
differences between the xylitol group and the L. salivarius
TI 2711 and the Ovalgen® DC groups (P = 0.003 and
P = 0.002, respectively).Table 3 Changes in levels of mutans streptococci and lactoba
capacity after taking the tablet [median (IQR)]
Group (n) L. salivarius WB21 L. salivarius T
Items (n = 17) (n = 16)
Mutans streptococci level 0.0 (−1.0 to 0.0) 0.0 (0.0 to 1
Lactobacilli level 3.0 (2.0 to 3.0) 2.5 (2.0 to 3
Salivary flow (mL per 3 min) 0.0 (−0.5 to 0.0) 0.0 (−0.4 to
Salivary pH 0.0 (0.0 to 0.2) 0.2 (0.0 to 0
Buffering capacity 0.0 (−0.4 to 0.3) 0.0 (−0.2 to
*The Kruskal-Wallis test was used to evaluate the differences among the four group
†Significantly different pairs: L. salivarius WB21 vs. Ovalgen® DC, P = 0.001; L. salivari
and L. salivarius TI 2711 vs. Xylitol, P = 0.002 (Wilcoxon rank-sum test).
§Significantly different pairs: L. salivarius TI 2711 vs. Xylitol, P = 0.003; and Ovalgen®Short-term administration trial
The levels of mutans streptococci had decreased after
2 weeks of oral administration of L. salivarius WB21-
containing tablets in all but one subject; there was a sig-
nificant difference between days 0 and 14 [6.0 (4.9 to 6.3)
to 5.5 (4.8 to 6.1) log CFU/mL; P = 0.039; Figure 1].
Discussion
Oral consumption of L. salivarius WB21 and TI 2711
did not show side effects related to advance of caries in
the oral cavity. In fact, those tablets provided better
resistance to caries risk factors compared to the xylitol
tablet. Mutans streptococci levels increased and salivary
flow and salivary buffering capacity decreased after
taking the xylitol tablet in the present study. In contrast,
the mutans streptococci level decreased in the group
taking oral L. salivarius WB21-containing tablets. A
reduction in mutans streptococci level was seen in 29.4%
of subjects in the L. salivarius WB21 group (5/17),
18.8% in the L. salivarius TI 2711 group (3/16), 38.5% in
the Ovalgen® DC group (5/13), and 16.7% in the xylitol
group (3/18). An increase in mutans streptococci level
occurred in 11.8% of subjects in the L. salivarius WB21
group (2/17), 31.3% in the L. salivarius TI 2711 group
(5/16), 30.8% in the Ovalgen® DC group (4/13), and
44.4% in the xylitol group (8/18). In addition, the explo-
ratory short-term administration trial with L. salivarius
WB21-containing tablets showed a reduction in levels of
mutans streptococci in saliva at 2 weeks.
Salivary flow, salivary pH, and salivary buffering capacity
did not change or increased after taking the L. salivarius
WB21 and TI 2711 tablets. No changes were noted in
salivary buffering capacity in the L. salivarius WB21 and
TI 2711 groups, although a reduction was seen in the
xylitol group. Medians salivary buffering capacity was
the same in the L. salivarius WB21 and TI 2711 groups,
but less variability was observed in the L. salivarius
TI 2711 group than in the L. salivarius WB21 group
(Table 3). A significant difference was detected incilli, salivary flow, salivary pH, and salivary buffering
I 2711 Ovalgen® DC Xylitol P value*
(n = 13) (n = 18)
.3) 0.0 (−1.0 to 1.0) 0.0 (0.0 to 2.0) 0.214
.0) 0.0 (0.0 to 0.5) 0.0 (−0.3 to 0.0) <0.001†
0.5) −0.5 (−1.0 to 0.0) −0.5 (−1.1 to 0.0) 0.172
.3) 0.1 (0.0 to 0.2) 0.0 (−0.1 to 0.3) 0.715
0.4) 0.2 (0.0 to 0.3) −0.3 (−0.6 to −0.1) 0.004§
s.
us WB21 vs. Xylitol, P = 0.001; L. salivarius TI 2711 vs. Ovalgen® DC, P = 0.007;






























P =  0.039
Figure 1 Changes in the numbers of mutans streptococci
(log CFU/mL) caused by continuous oral administration of
L. salivarius WB21-containing tablets for 2 weeks. A significant
difference between day 0 and day 14 was shown by the Wilcoxon
signed-rank test (P = 0.039).
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group and the xylitol group.
Salivary flow did not differ among the four groups in
the present study, although it increased in the L. salivarius
TI 2711 group [from 7.3 (5.8 to 8.8) to 8.0 (6.1 to 9.3) mL
per 3 min]. The trend toward increased salivary pH in the
L. salivarius TI 2711 group may have been caused by the
increase in salivary flow (Table 3). No changes in salivary
flow, salivary pH, and salivary buffering capacity were
noted in the L. salivarius WB21 group. In previous stud-
ies, salivary flow was significantly increased by oral admin-
istration of L. salivarius WB21-containing products for
2 weeks [9,24]. Salivary pH and buffering capacity did not
change in those studies. The increase in saliva in those
studies may have been caused by continuous ingestion of
the tablets.
Our results suggest that L. salivarius strain-containing
tablets can be used safely without increasing the caries
risk, and that their oral administration may contribute
to caries control in healthy adults. An open-label trial is
insufficient to confirm a positive effect of lactobacilli on
caries prevention because placebo effects were evident
in previous double-blind trials [7,9,10]. Therefore, a
double-blind randomized placebo-controlled trial is re-
quired to confirm the effect of L. salivarius-containing
tablets on caries risk factors.
Tablets containing egg yolk antibodies against S.
mutans cell-associated glucosyltransferase (anti-CA-gtf
IgY, Ovalgen® DC) and xylitol tablets were used for
comparison in the present study. All products used
contained xylitol, a non-fermentable sugar alcohol
that cannot be used as an energy source in the metabolism
of cariogenic bacteria [24]. In this study, the level of
mutans streptococci in the saliva increased in 44.4% ofsubjects in the xylitol group. The gum test was performed
twice, and therefore more mutans streptococci may have
been removed from the surface of teeth. The flow rate,
pH, and buffering capacity of saliva were reduced or
remained unchanged by oral consumption of the xylitol
tablets. A clinical trial using xylitol gum found that the
effects of chewing are essential for the stimulation of
salivary flow and the resulting recovery of pH levels and
reduction of S. mutans levels in saliva [25]. It was
suggested that licking a xylitol tablet does not affect
the quality of saliva.
The Ovalgen® DC tablet significantly increased salivary
buffering capacity compared with the xylitol tablet,
although the cause is unclear. The rate of reduction in
mutans streptococci levels in the Ovalgen DC® group
(38.5%) was greater compared with the xylitol group
(16.7%), although the differences between the groups were
not significant. It has been reported that anti-CA-gtf IgY
suppressed the development of caries lesions in rats
[26], and tablets containing anti-CA-gtf IgY significantly
reduced the numbers of mutans streptococci in a 5-day
double-blind placebo-controlled trial [27]. The mean
anaerobic bacterial counts were not significantly dif-
ferent before and after the trial [27], indicating that
Ovalgen® DC is specific for dental cariogenic species.
In contrast, lactic acid bacteria affect various bacteria
residing in the oral cavity and have various functions
that differ among species, including aggregation, com-
petition for adhesion sites, nutrients, and growth fac-
tors, production of antimicrobial compounds such as
acid, hydrogen peroxide, and bacteriocins, and effects
on the immune response [28]. The mechanisms by
which L. salivarius WB21 and TI 2711 reduce caries
risks are unclear, but coaggregation, growth inhibition
of mutans streptococci, and reduced plaque acidogenicity
have been reported as potential mechanisms by which
lactic acid bacteria prevent dental caries [29-31]. Keller
et al. [29] investigated the in vitro abilities of eight pro-
biotic Lactobacillus strains (L. plantarum 299v, 931, L.
rhamnosus GG, LB21, L. paracasei F19, L. reuteri ATCC
PTA 5289, DSM 17938 and L. acidophilus La5) to coag-
gregate and inhibit mutans streptococci. All lactobacilli
displayed coaggregation activity and inhibited the
growth of clinical mutans streptococci. The growth
inhibition was strain-specific and dependent on both
pH and cell density [29]. An in vitro experiment also in-
dicated that lactic acid production in suspensions of
plaque and probiotic lactobacilli was strain-dependent
[32]. The salivary pH was not changed by oral consump-
tion of L. salivarius WB21 or TI 2711 in this study. A
previous clinical study using oil containing L. salivarius
WB21 indicated no changes in salivary pH after 2 weeks
of treatment [9]. The short-term consumption of L.
rhamnosus GG and L. reuteri for 2 weeks had no effect
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trast, a significant reduction in plaque acidogenicity was
found with long-term (6 weeks) consumption of L. brevis
CD2 [31]. Furthermore, clinical assessments indicated that
the effects of probiotics varied depending on host suscep-
tibility. In fact, the levels of mutans streptococci in several
participants were increased after oral consumption of
L. salivarius strains in the present study. Further studies
of the characteristics of probiotic strains and the host
responses are required to determine their appropriate ap-
plications, doses and treatment durations.
Conclusion
In conclusion, our results indicate that administration
of tablets containing the probiotic lactic acid bacteria
L. salivarius WB21 and TI 2711 for plaque control,
periodontal health, and oral malodor is safe and helps to
prevent the development of dental caries.
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